The Zhitong Finance App learned that Damo released a research report saying that after the second quarter results of CSPC Group (01093), the model was updated. Earnings estimates per share for 2026, 2027 and 2028 were raised by 10%, 11%, and 10%, respectively, mainly reflecting the acceleration of business development revenue collection and observed revenue recording trends. At the same time, it is also expected that the finished drug sales portfolio will record resilient growth, and the industry's headwinds have largely been digested. The target price was raised from HK$11 to HK$12. The rating is “gain”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.